Hooman Noorchashm
Overview
Explore the profile of Hooman Noorchashm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blumberg E, Noll J, Tebas P, Fraietta J, Frank I, Marshall A, et al.
JCI Insight
. 2022 May;
7(11).
PMID: 35536669
BACKGROUNDCOVID-19 remains a global health emergency with limited treatment options, lagging vaccine rates, and inadequate healthcare resources in the face of an ongoing calamity. The disease is characterized by immune...
2.
Shenai M, Rahme R, Noorchashm H
Cureus
. 2021 Dec;
13(10):e19102.
PMID: 34868754
We present a systematic review and pooled analysis of clinical studies to date that (1) specifically compare the protection of natural immunity in the COVID-recovered versus the efficacy of complete...
3.
4.
5.
Redfield R, Rodriguez E, Luo Y, Rostami S, Parsons R, Noorchashm H, et al.
J Surg Res
. 2013 Nov;
187(1):310-5.
PMID: 24267616
Background: Long-lived plasma cells (PCs) that form after alloantigen sensitization produce donor-specific alloantibodies that generate a positive serum crossmatch and preclude transplantation. New approaches for desensitization, including PC depletion with...
6.
Naji A, Noorchashm H, Cancro M
Semin Immunol
. 2012 Apr;
24(2):75-6.
PMID: 22483169
No abstract available.
7.
Parsons R, Yu M, Vivek K, Zekavat G, Rostami S, Ziaie A, et al.
Transplantation
. 2012 Jan;
93(7):676-85.
PMID: 22262127
Background: Immunologic rejection is a major barrier to successful long-term outcomes in clinical transplantation. The importance of B lymphocytes-and their secretory products, alloantibodies-in the pathogenesis of allograft rejection is accepted....
8.
Redfield R, Parsons R, Rodriguez E, Mustafa M, Cassuto J, Vivek K, et al.
Clin Transplant
. 2011 Oct;
26(3):489-94.
PMID: 22032287
Background: ABO compatibility creates a disadvantage for O and B renal allograft candidates. A2 ABO incompatible transplant may decrease waiting times and generate equivalent graft survival to an ABO compatible...
9.
Redfield 3rd R, Rodriguez E, Parsons R, Vivek K, Mustafa M, Noorchashm H, et al.
Curr Opin Immunol
. 2011 Oct;
23(5):685-91.
PMID: 21982511
T lymphocytes are the primary targets of immunotherapy in clinical transplantation. However, B lymphocytes are detrimental to graft survival by virtue of their capacity to present antigen to T cells...
10.
Parsons R, Redfield 3rd R, Rodriguez E, Mustafa M, Vivek K, Murayama M, et al.
Semin Immunol
. 2011 Oct;
24(2):109-14.
PMID: 21978627
The current mainstay of immunotherapy in clinical transplantation is T lymphocyte directed. However, it has long been appreciated that the emergence of an alloimmune response mounted by the B lymphocyte...